For decades, cannabis was a punchline in mainstream medicine. Today, it’s the subject of peer-reviewed journals, randomized trials, and serious pharmaceutical investment. A comprehensive new review published in April 2026 in the journal Pharmaceutics — Cannabinoids for Dermatological Applications: Mechanistic Insights, Clinical Evidence, and Emerging Nanotechnology-Enabled Delivery Strategies — brings together years of research to map out exactly how cannabinoids interact with human skin, what conditions they might treat, and why getting them into the right layer of your skin turns out to be one of the hardest problems in modern pharmacy.
The findings paint a picture that is both more exciting and more nuanced than the marketing on your average CBD lotion would have you believe.
Key Takeaways
- Human skin contains its own endocannabinoid system, with CB1 and CB2 receptors present in keratinocytes, sebocytes, fibroblasts, and immune cells — meaning cannabinoids have real, biologically relevant targets in skin tissue.
- Conditions with early clinical evidence include psoriasis, atopic dermatitis (eczema), acne, chronic itch, scleroderma, dermatomyositis, and certain skin cancers.
- Most existing clinical trials are small, short, and lack placebo controls — the science is promising but not yet definitive.
- CBD and related cannabinoids are notoriously difficult to formulate: they are oily, unstable, and do not penetrate skin easily.
- Nanotechnology-based delivery systems (liposomes, nanoemulsions, lipid nanoparticles) are emerging as the most credible path to making cannabinoid skin therapies actually work reliably.
Why Your Skin Is Essentially Running Its Own Cannabis System
To understand why anyone is putting CBD in a face cream, you first need to know that your body was producing cannabinoid-like molecules long before the cannabis plant entered the picture. The endocannabinoid system (ECS) is a biological regulatory network that manages everything from pain and inflammation to mood and immune response — and it is richly expressed in the skin.
Researchers have identified at least nine endocannabinoids produced naturally in human skin, including anandamide (sometimes called the “bliss molecule”) and 2-arachidonoylglycerol (2-AG). These compounds bind to CB1 and CB2 receptors embedded in skin cells, as well as to a family of ion channels called TRP receptors and a nuclear receptor called PPARγ. Together, these pathways regulate how fast skin cells divide, how much oil sebaceous glands produce, how fibroblasts lay down collagen, and how aggressively immune cells respond to perceived threats.
When this system falls out of balance — through genetics, stress, environmental damage, or disease — you get inflammation, abnormal cell growth, or barrier dysfunction. Which is, incidentally, exactly what happens in psoriasis, eczema, acne, and a host of other chronic skin conditions.
Cannabis-derived cannabinoids like CBD and THC interact with these same receptors and channels. That’s not coincidence — it’s the reason this research field exists at all. If you’re new to CBD and want a solid foundation before diving into the dermatology science, our complete guide to CBD covers everything from how it’s extracted to how it moves through the body.
What the Science Actually Says About CBD and Skin Disease
Psoriasis: Slowing Down Runaway Skin Cells
Psoriasis affects roughly 2-3% of the global population and is driven by an immune system that triggers skin cells to multiply far faster than they should, producing the characteristic thick, inflamed plaques. CBD appears to interrupt this process at multiple points simultaneously.
In laboratory studies, CBD has been shown to suppress the release of pro-inflammatory cytokines — signaling proteins like TNF-α, IL-17A, and IL-22 that drive psoriatic inflammation. It also inhibits a key inflammatory pathway called NF-κB, and modulates the JAK/STAT signaling cascade that mediates the immune response downstream of IL-23, one of the central drivers of psoriatic disease. In plain terms: CBD appears to put the brakes on several of the molecular “alarm signals” that tell skin cells to overproduce.
Clinically, small studies have shown meaningful improvements. In one retrospective cohort, patients applying CBD ointment twice daily for three months saw significant improvements in their PASI scores (a standardized measure of psoriasis severity) along with increased skin hydration — with no reported adverse effects. A randomized single-blind trial of a topical formulation combining CBD and THC reduced disease severity and improved quality of life over 56 days, also with no blood chemistry changes. A more rigorous double-blind trial published in 2026 found CBD oil to be well-tolerated, with modest improvements in sleep and itch, though it did not significantly reduce psoriasis severity on its own — suggesting that dose and formulation matter enormously.
The honest summary: cannabinoids show real mechanistic logic for psoriasis, early clinical signals are positive, but large, properly controlled trials are still absent.
Atopic Dermatitis: Calming the Itch-Scratch Cycle
Eczema — or atopic dermatitis — is the most common inflammatory skin disease in the world. It is characterized by a dysfunctional skin barrier, overactive Th2 immune responses, and the kind of persistent itching that disrupts sleep and quality of life far more than its surface appearance suggests.
The ECS turns out to be deeply involved in both barrier function and itch signaling. Research in mice has shown that keratinocytes lacking CB1 receptors produce more of a pro-inflammatory signaling molecule called TSLP, driving the very Th2 inflammation that defines eczema. CB1 receptor agonists, applied topically, have been shown to reduce mast cell activity, lower skin thickness, decrease trans-epidermal water loss, and improve barrier hydration.
Clinical evidence supports a similar picture. A large multinational observational study involving over 2,400 patients found that palmitoylethanolamide (PEA), an endocannabinoid-related compound, significantly reduced eczema symptoms including scaling, dryness, and itch while also improving sleep and reducing steroid use. A placebo-controlled trial of JW-100 — a CBD-aspartame combination cream — showed significant reductions in eczema severity scores within just two weeks. Multiple smaller studies of CBD-based creams, gels, and shampoos report consistent improvements in itch and barrier function.
Cannabigerol (CBG), a less-studied cannabis compound, has also shown promise in preclinical models, reducing skin inflammation and improving barrier function in mouse models of eczema.
Acne: Targeting the Oil Glands Directly
Acne is, at its core, a problem of too much oil, the wrong bacteria, and inflammation — a combination that CBD seems positioned to address on all three fronts simultaneously.
Human sebaceous glands express both CB1 and CB2 receptors. In a landmark 2014 study using human sebocytes (the oil-producing cells), CBD was shown to suppress abnormal lipid production, inhibit cell proliferation, and reduce inflammation — without meaningful toxicity at therapeutic doses. Importantly, CBD’s anti-acne action appears to operate through the TRPV4 channel and MAPK/ERK signaling pathways, making it somewhat independent of the classical cannabinoid receptors.
Hemp seed extracts have separately demonstrated antibacterial activity against Cutibacterium acnes, the bacterium most associated with inflammatory acne, while also suppressing key inflammatory pathways in skin cells.
A phase II clinical trial of BTX 1503, a CBD-based topical solution, demonstrated a dose-dependent reduction in inflammatory lesion counts in patients with moderate to severe acne — with a good safety profile. The results were promising enough to warrant continued investigation.
Chronic Itch: Quieting the Nerves
Pruritus — pathological itching — affects a significant fraction of patients with kidney disease, liver disease, inflammatory skin conditions, and cancer. It is notoriously difficult to treat, and conventional antihistamines frequently fail because itch in these contexts is often not histamine-driven.
The ECS offers a distinct angle. CB1 and CB2 receptors are expressed on the sensory nerve fibers that run through skin, and activating them can reduce neuronal excitability and dampen itch signaling at the level of the nerve, rather than at the immune level. In human studies, a cannabinoid receptor agonist applied to skin reduced histamine-induced itch, flare reactions, and skin blood flow — through mechanisms entirely separate from antihistamine pathways. PEA-based creams reduced itching in over 80% of patients with uremic pruritus in an early observational study.
This is one area where the mechanistic rationale is particularly strong, even if the clinical evidence base remains thin.
Scleroderma: Fighting the Body That Scars Itself
Systemic sclerosis (scleroderma) is a rare and difficult autoimmune disease in which the immune system attacks connective tissue, producing fibrosis — hardening and scarring — in skin and internal organs. Dermal fibroblasts express CB2 receptors, and activating CB2R appears to suppress the pro-fibrotic signaling cascades that drive collagen overproduction.
The cannabinoid drug lenabasum (a synthetic CB2 agonist) has been the furthest along in clinical testing for this indication. Phase II trials showed improvements in skin scores and inflammatory gene expression. However, a recently completed Phase III trial in diffuse cutaneous systemic sclerosis did not demonstrate a statistically significant improvement over placebo on the primary endpoint — a sobering reminder that early phase results do not always hold up. Analysis suggests that patients with higher baseline CB2R expression may respond better, pointing toward a future of biomarker-guided patient selection.
Skin Cancer: A Complex Picture
The relationship between cannabinoids and skin cancer is real, but significantly more complicated than “CBD fights cancer” headlines suggest.
Cannabinoid signaling has demonstrated both anti-tumor and, in some contexts, pro-tumor effects, depending on the concentration, the specific receptor involved, and the cancer type. In preclinical models of non-melanoma skin cancer, cannabinoid receptor agonists have reduced tumor growth by inducing apoptosis (programmed cell death) and blocking the formation of new blood vessels that tumors need to survive. In melanoma models, THC and CBD have shown superior effectiveness in reducing cell survival and tumor formation compared to standard chemotherapy drugs in certain cell lines.
However, CB1 receptor activation may promote tumor growth in some melanoma contexts — the same receptor that is anti-tumor in one setting becomes pro-tumor in another. This is the endocannabinoid system at its most confounding, and it underscores why no one should be treating skin cancer with a CBD cream based on current evidence.
The Delivery Problem: Why Getting CBD Into Skin Is Harder Than It Sounds
Here is a central irony of cannabinoid skin research: the very property that makes CBD biologically useful — its ability to dissolve in fats and penetrate biological membranes — also makes it deeply problematic to formulate.
CBD is highly lipophilic (fat-loving), poorly soluble in water, chemically unstable when exposed to light, heat, or oxygen, and tends to get stuck in the outermost layers of skin rather than penetrating to where inflammation actually lives. It also degrades quickly in the body and shows enormous variability from person to person in how much actually reaches the target tissue.
Most commercial CBD topicals are not particularly well-designed to solve these problems. A standard cream might deliver CBD to the surface of the skin, but getting meaningful concentrations into the viable epidermis and dermis — where the relevant receptors actually are — is a pharmaceutical engineering challenge.
Nanotechnology to the Rescue
This is where the most genuinely exciting developments in cannabinoid dermatology are happening. Researchers are building nanoscale delivery vehicles — structures measured in billionths of a meter — designed to carry CBD deeper into skin, protect it from degradation, and release it in a controlled manner where it’s actually needed.
The main platforms under investigation include lipid nanoparticles and nanostructured lipid carriers (tiny fat-based particles that closely resemble skin’s own lipid matrix), nanoemulsions (oil droplets suspended in water at nanoscale, dramatically improving CBD’s ability to penetrate), liposomes (microscopic spherical vesicles that can fuse with cell membranes), micellar systems (molecular detergent-like structures that solubilize CBD), and hydrogel matrices that provide sustained, controlled release.
The results in laboratory and ex vivo human skin models are striking. CBD-loaded nanoemulsions reduced inflammatory biomarkers including IL-6 and MMP-1, while restoring normal collagen levels under stress conditions, in 2025 experiments on actual human skin tissue. Nanostructured lipid carrier gels designed for skin cancer applications demonstrated improved skin retention and tolerability compared to conventional formulations. Solid lipid nanoparticles loaded with CBD reduced markers of psoriasis severity in model systems, achieving drug entrapment efficiencies of 85%.
Gold and silver nanoparticles synthesized using CBD — exploiting the molecule’s chemical properties to build the particles themselves — have demonstrated low toxicity in keratinocytes and enhanced anticancer potential in early studies.
The critical caveat: virtually all of these nanoformulation studies are preclinical. The gap between an impressive ex vivo skin penetration result and a successful clinical trial is substantial, and that gap has not yet been bridged for any cannabinoid nanoformulation.
What Comes Next
The authors of the review are clear-eyed about what the field still needs. Standardized formulation design — meaning consistent, pharmaceutically defined products rather than variable plant extracts — is a prerequisite for meaningful clinical trials. Finite-dose application models that reflect how people actually use skin products, rather than infinite-dose laboratory flooding, are necessary to predict real-world behavior. Robust randomized controlled trials comparing cannabinoid formulations against established treatments like topical steroids or retinoids have not yet been done at scale.
Regulated cannabinoid medicines — Epidiolex (purified CBD) approved for epilepsy, Sativex (standardized THC/CBD) for multiple sclerosis spasticity — demonstrate that when pharmaceutical-grade manufacturing and clinical rigor are applied to cannabinoids, the drugs do work and can be approved. The dermatology field is at an earlier stage of that journey.
The endocannabinoid system in skin is real, well-characterized, and biologically plausible as a therapeutic target. The molecules that interact with it show genuine activity in disease models. The delivery technology to get them where they need to go is advancing rapidly. What the field needs now is the same disciplined, expensive, time-consuming process of large controlled trials that any serious medicine requires — and there is enough scientific signal to make that investment worthwhile.
FAQ
There is genuine biology behind CBD’s potential in skin diseases — the endocannabinoid system is real and well-documented in skin tissue, and laboratory and early clinical studies show meaningful effects on inflammation, oil production, and itch. However, most clinical trials to date are small and lack proper controls, so the evidence is not yet strong enough to make definitive treatment recommendations. The gap between “shows promise” and “proven medicine” is real and significant. For a broader overview of what CBD is, where it comes from, and how it works across different contexts, see our complete CBD guide.
Some patients report symptomatic improvement with over-the-counter CBD topicals, and early clinical trials support the plausibility of benefit. However, commercial CBD products vary enormously in quality, concentration, and formulation design, meaning there is no guarantee that any given product delivers CBD where it needs to go in meaningful amounts. If you have a diagnosed skin condition, any CBD product should be used as a complement to, not a replacement for, medical treatment — and discussed with your dermatologist.
No. Topical cannabidiol (CBD) is non-psychoactive by itself, and when applied to skin, systemic absorption is extremely low — studies of even large-dose transdermal formulations show only trace amounts reaching the bloodstream. Topical THC-containing products exist in some markets but are formulated at concentrations and in ways that also produce minimal systemic exposure.
Two things: formulation science and clinical evidence. CBD is chemically difficult to deliver into skin in therapeutic amounts — it degrades, gets stuck, and varies between products. Advanced nanotechnology formulations are solving this in the lab but have not yet been proven in large clinical trials. Until there are standardized, pharmaceutical-grade formulations evaluated in properly controlled studies against existing standard-of-care treatments, cannabinoid dermatology remains a promising but unproven therapeutic area.
Disclaimer: This article is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The research discussed is based on a peer-reviewed scientific review and reflects the current state of preclinical and early clinical evidence, which remains preliminary in many areas. Individuals with skin conditions should consult a qualified healthcare professional before starting, stopping, or changing any treatment. The Cannex does not endorse any specific product, brand, or formulation mentioned in this article.
